The name is the button.

An agent writes the code now, and a human thumb hovers over Accept all a hundred times a day. The honest question of this decade is what, exactly, you just accepted. So I read the diff.

Eight years as a backend engineer in Stockholm, back in Tokyo since 2023, and I still ship something small most nights, usually badly. My one rule: the only real review of a model is the thing you built with it. That is why there is no leaderboard on this site.

Around a hundred and forty sources come through — the labs' own posts, the papers, the tools, the runtimes and languages nobody is watching yet, the chip under the demo, and the newsletters people actually forward. What is moving gets counted so the week reads at a glance, and every few days I explain one mechanism in plain words.

A story here is a headline, a short excerpt, one image and the link to whoever wrote it. We never reproduce the post; the images belong to their authors. A post written in Japanese appears in Japanese, exactly as it was published, and the link goes to the original.

— Yuki Halvorsen, Tokyo

← Accept All Archive

Tech in AsiaAsia

Series SEA: Who’s investing in the region’s biotech startups?

September 24

We've compiled a list of investors that are pouring money into Southeast Asia’s biotech startups.

Read at Tech in Asia ↗

One letter a week, in your inbox.

Latest

Series SEA: Who’s investing in the region’s biotech startups?

More from Tech in Asia on Accept All

AsiaTencent launches TenPayGo for WeChat Pay travelers Tech in Asia

AsiaY Combinator backs US AI startup ByteAsk in $1m round Tech in Asia

AsiaGobi-backed Bitsmedia lays off 21 employees Tech in Asia

AsiaNUS Enterprise becomes NUSX, adds AI tool Tech in Asia

AsiaAnyMind to add Alibaba Qwen to Asia live commerce Tech in Asia

AsiaMeta, EssilorLuxottica expand Ray-Ban AI glasses to new markets Tech in Asia